top of page
  • Recruiting

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

Updated: May 23, 2022

PRISM High Risk Smoldering Multiple Myeloma

NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)

prism smoldering myeloma

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or symptomatic multiple myeloma.

The names of the study drugs involved in this study are:

Daratumumab (also called Darzalex Faspro)

Bortezomib (also called Velcade)

Lenalidomide (also called Revlimid)



Omar Nadeem


Janssen, LP

Information provided by (Responsible Party):

Omar Nadeem, Dana-Farber Cancer Institute


United States, Massachusetts

Brigham and Women's Hospital Recruiting

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215 Identifier: NCT04775550

Official Title: B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma

First Posted: March 1, 2021


Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute

Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


* Bortezomib (Velcade)

* Lenalidomide (Revlimid)

* Dexamethasone (Decadron)

* Daratumumab (Darzalex)

Posts Archive
bottom of page